Baker Botts
Recent News About Baker Botts
-
Recent patent infringement cases filed in the Eastern District of Texas
Recent patent infringement cases filed in the Eastern District of Texas, Feb. 6-10. -
****FOR PRINT*** Texas SC overturns $8M Vioxx verdict
Hecht AUSTIN (Legal Newsline) - The Texas Supreme Court on Friday overturned a huge jury award in favor of a Texas man who died after briefly taking Vioxx, an arthritis drug Merck & Co. eventually pulled from the market. -
Recent patent infringement/false patent marking cases filed in the Eastern District of Texas
Recent patent infringement/false patent marking cases filed in the Eastern District of Texas, April 4-8, 2011. -
Recent patent infringement/false marking suits filed in the Eastern District of Texas
Recent patent infringement/false marking suits filed in the Eastern District of Texas, Sept. 28-Oct. 4, 2010. -
Recent patent infringement cases filed in the Eastern District of Texas
Recent patent infringement cases filed in the Eastern District of Texas, May 29-June 2, 2009 -
Recent patent infringement suits filed in U.S. District Courts
Recent patent infringement suits filed in the Eastern District of Texas, Jan. 22-23, 2009 -
Recent patent/copyright infringement cases filed in U.S. District Courts
Marshall Division, Eastern District of Texas -
Recent patent/copyright infringement cases filed in U.S. District Courts
Marshall Division, Eastern District of Texas -
$156 M verdict against ATT in patent suit
Doug Cawley of McKool Smith A federal jury delivered a $156 million verdict against AT&T Friday in a patent infringement lawsuit brought by a Dallas-based communications company. -
Texas court dismisses claim of VIOXX user who said Merck failed to properly warn of the alleged risks
WHITEHOUSE STATION, N.J., April 20, 2007 - Merck & Co., Inc. said today that a Texas court overseeing the Texas litigation rejected a plaintiff's claim that she was not properly informed of the medicine's alleged risks because, in fact, the VIOXX label contained a U.S. Food and Drug Administration (FDA)-approved warning. The court order in the case, Ledbetter v. Merck, could have an impact on most